SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (OnlineFirst PDF)
Right arrow All Versions of this Article:
0269881108091596v1
23/1/94    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sellman, J D
Right arrow Articles by Beasley, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sellman, J D
Right arrow Articles by Beasley, R
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ETHANOL
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Article

Should ethanol be scheduled as a drug of high risk to public health?

J D Sellman1*, G M Robinson2, and R Beasley3

1 Professor of Psychiatry and Addiction Medicine, Director, National Addiction Centre, University of Otago, Christchurch, PO Box 4345, Christchurch Mail Centre, Christchurch 8140, New Zealand
2 Chief Medical Officer, Capital and Coast District Health Board, Wellington, New Zealand; and Director, Alcohol and Drug Programmes, Medical Research Institute of New Zealand, Wellington Hospital, Private Bag 7902, Wellington South 6242, New Zealand
3 Director, Medical Research Institute of New Zealand, PO Box 10055, Wellington 6413, New Zealand

* To whom correspondence should be addressed.


   Abstract

Abstract

Six criteria described in the New Zealand Misuse of Drugs Act and used by the Expert Advisory Committee on Drugs (EACD) for determining the risk of a drug to public health were examined in relation to ethanol, using {gamma}-hydroxybutyric acid (GHB) as a comparator drug. GHB is an ideal candidate for use as a comparator because it is a sedative substance very similar to ethanol and has been previously investigated by the EACD using these six criteria. GHB was subsequently classified as a Class B1 drug under the Misuse of Drugs Act, that is, as a prohibited drug of high risk to public health. The dangerousness level of ethanol was found to be at least similar to that of GHB in this analysis. This highlights a major discrepancy in public policy.

Key Words: alcohol, classification, drugs of abuse

First published on June 26, 2008, doi:10.1177/0269881108091596

Journal of Psychopharmacology 2009;23:94.

A more recent version of this article appeared on January 1, 2009


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement